Phase II/III Clinical Study of R484iv (Ibandronic acid) for Primary Osteoporosis
Phase 2
- Conditions
- Osteoporosis
- Registration Number
- JPRN-jRCT2080220364
- Lead Sponsor
- Chugai Pharmaceutical Co., Ltd. Taisho Pharmaceutical Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Osteoporosis patients with fragile bone fracture, low bone mineral density and vertebral fracture
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Incidence of non-traumatic vertebral fracture (including deterioration of prevalent fracture)
- Secondary Outcome Measures
Name Time Method